"I have liked this stock from day one," he said. Many people are turned off by Intuitive Surgical because they don't know what it does, Cramer said. These people panicked on Friday and helped keep the stock down.

Intuitive Surgical makes surgery less invasive, which means people get in and out of the hospital faster, Cramer explained. Cost containment in health care is one of the best trends around, he said, and insurers and patients are powering it.

One of the reasons the company beat its quarter "so handily" is that people don't understand its business model, he said. It may make some really high-tech gear, but at the end of the day, its business model is like Gillette's razor-blade model.

People think the company will run out of growth sooner or later because it won't have any place left to sell its machines, but this is just the beginning for Intuitive, Cramer said. However, Cramer said that when all of its machines are in place, that's when its growth will go up more and more.

Places that use the machines to perform a surgery need to buy disposable add-ons, he explained. This is where Intuitive Surgical makes its money, just like Gillette makes its money with its disposable razor blades.

The only thing not to like about Intuitive is its $285 price tag, but that's just an "illusion," Cramer said. This stock has "king growth" and should go higher. He set his new price target for Intuitive at $358.

Sticking with Schering-Plough

Cramer told viewers he's been reading through Microtrends: The Small Forces Behind Tomorrow's Big Changes by Mark Penn, and it has helped him think of Schering-Plough (SGP Quote) as a stock worth considering.

Skin cancer, he said, is the most common type of cancer and its mortality rate is up 50% since 1970s, but most people are not aware of this.

Cramer said he's liked Schering as a turnaround story for a while, but today the stock got pummeled. Its cholesterol division was flat and the Street was looking for more growth. However, Cramer said he's leaning toward believing it's an entry point to get into the stock because it has many phase III drugs in the works, including one for prostate cancer and one for female infertility. "These could be huge," he said.

That said, Cramer welcomed CEO Fred Hassan to the show and asked him what went wrong with the stock.

"Today is no different than yesterday, and this is what I call the no-guidance effect," Hassan said. "Having a no-guidance policy, there are some quarters where there is an undershoot and some quarters when there is an overshoot."

It's all relative to what people see in the company, he continued. However, Schering is "a long-term story," and if market players compare the company to its peers, they'll see what Schering's all about, Hassan said.

Further, he believes Schering is "going to be transformed" with its acquisition of Organon BioSciences, the human and animal health business of Dutch chemical firm Akzo Nobel.

Cramer said he's sticking with Hassan, calling the chief executive "a moneymaker."

Seaspan a Good Bet

Next, Seaspan's (SSW Quote) Gerry Wang joined Cramer on his show, where the chief executive said he feels "very good" about his company's growth.

Wang said he has seen demand in the container shipping industry increase by more than 10% in the last 10 years and expects continued growth. Moreover, Seaspan's fixed rates insulates the company from the volatility of market rates, he said.

Cramer said he still prefers dry bulk shipping, but believes "Wang has a good one in Seaspan."

Lightning Round

Cramer was bullish on Celgene (CELG Quote), eBay (EBAY Quote), Halliburton (HAL Quote) and Under Armour (UA Quote).

Cramer was bearish on Sangamo Biosciences (SGMO Quote), Virgin Mobile (VM Quote), Superior Energy Services (SPN Quote), Amtrust Financial Services (AFSI Quote) and Charter Communications (CHTR Quote).

During the "Sudden Death" round, Cramer was bullish on Cypress Semiconductor (CY Quote). He was bearish on Unit (UNT Quote).

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by clicking here.

For more of Cramer's insights during the Lightning Round, click here.